scispace - formally typeset
F

Federica Barutta

Researcher at University of Turin

Publications -  60
Citations -  2226

Federica Barutta is an academic researcher from University of Turin. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 23, co-authored 54 publications receiving 1679 citations.

Papers
More filters
Journal ArticleDOI

Urinary exosomal microRNAs in incipient diabetic nephropathy.

TL;DR: In this article, the miRNA expression in urinary exosomes from type 1 diabetic patients with and without incipient diabetic nephropathy was assessed and miR-145 levels were increased and this was paralleled by miR145 overexpression within the glomeruli.
Journal ArticleDOI

Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.

TL;DR: In experimental type 1 diabetes, theCB1 receptor is overexpressed by glomerular podocytes, and blockade of the CB1 receptor ameliorates albuminuria possibly via prevention of nephrin, podocin, and ZO-1 loss.
Journal ArticleDOI

Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy

TL;DR: The CB2 receptor is expressed by podocytes, and in experimental diabetes, CB2 activation ameliorates both albuminuria and podocyte protein loss, suggesting a protective effect of signaling through CB2 in DN.
Journal ArticleDOI

Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes

TL;DR: In human podocytes, MCP-1 binding to the CCR2 receptor induced a significant reduction in nephrin both mRNA and protein expression via a Rho-dependent mechanism, suggesting that the MCP/CCR2 system may be relevant in the pathogenesis of proteinuria in diabetes.
Journal ArticleDOI

Role of the endocannabinoid system in diabetes and diabetic complications.

TL;DR: An update on the contribution of the ECS to the pathogenesis of diabetes and diabetic microvascular (retinopathy, nephropathy and neuropathy) and cardiovascular complications is provided and the therapeutic potential of targeting the E CS is discussed.